SIGN UP FOR THE HAEGARDA ADVOCATE PROGRAM

The HAEGARDA Advocate Program is available for patients or caregivers to connect with others who have personal experience with hereditary angioedema (HAE) and HAEGARDA®, C1 Esterase Inhibitor Subcutaneous (Human).

Please enter the following information, which will be used as part of the verification process for enrollment (*required).

Please agree to the terms below.

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy. If you chose to provide information about your physician, CSL Behring will not contact your physician regarding you or your treatment.

By submitting this form, you are consenting to disclose any information provided, including your name, email address, address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may also receive relevant information, including marketing information, from CSL Behring Entities by mail, email, telephone and/or SMS/text message in the future to provide information or to offer enrollment in educational programs and programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt out from receiving communications from CSL Behring Entities at any time.

For any questions about the HAEGARDA Advocate Program or to register by phone, please call us at 1-844-573-7021.

If you would like to contact HAEGARDA ConnectSM, please call 1-844-HAEGARDA (1-844-423-4273), Monday through Friday from 8 AM to 8 PM ET.

*Advocates are not healthcare providers or medical experts and are compensated for their participation. For medical questions, you should contact your physician.

You are now leaving the current website.

Do you want to continue?